Article Data

  • Views 1739
  • Dowloads 190

Original Research

Open Access

Serum laminin levels in eosinophilic and non-eosinophilic chronic obstructive pulmonary disease patients

  • Gulay Dasdemir Ilkhan1
  • Hakan Celikhisar2

1Tire Public Hospital, Department of Chest Diseases, Tire, Izmir, Turkey

2Esrefpasa Metropolitan Municipality Hospital, Department of Chest Diseases, Izmir, Turkey

DOI: 10.22514/sv.2021.018 Vol.17,Issue 2,March 2021 pp.188-192

Published: 08 March 2021

*Corresponding Author(s): Gulay Dasdemir Ilkhan E-mail:


Aim: To compare serum laminin levels in eosinophilic and non-eosinophilic (neutrophilic) COPD patients and to define its association with disease severity.

Material and Method: This prospective study included patients with mild, moderate, severe, and very severe stable COPD and a control group of patients with a history of smoking but with no signs or symptoms of COPD. Spirometric measurements and Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, was used to define the disease severity. Blood eosinophil percentage was recorded from complete blood counts. Serum laminin levels were measured in all patients.

Results: A total of 216 patients were included in the study. Ninety were in the eosinophilic COPD, 90 were in the non-eosinophilic COPD and 36 were in the control groups. In both COPD groups, serum laminin levels were significantly higher than in the control group (P = 0.001). In the eosinophilic COPD group, serum laminin levels were significantly higher than the non-eosinophilic COPD group (P = 0.001). With an increase in COPD severity, laminin levels were higher in both COPD groups (P = 0.001). In correlation analysis performed in all COPD patients, laminin levels were positively correlated with eosinophilia percentage (r = 0.316, P = 0.001) and negatively correlated with the FEV1/FVC ratio (r = -0.160, P = 0. 032).

Conclusion: Laminin has an important role in eosinophilic COPD and increased serum laminin levels are associated with an increase in serum eosinophilia percentage and a decrease in respiratory capacity.


COPD severity; Eosinophilic COPD; Laminin; Non-eosinophilic-COPD

Cite and Share

Gulay Dasdemir Ilkhan,Hakan Celikhisar. Serum laminin levels in eosinophilic and non-eosinophilic chronic obstructive pulmonary disease patients. Signa Vitae. 2021. 17(2);188-192.


[1] Crisafulli E, Torres A. COPD 2017: a year in review. Journal of Chronic Obstructive Pulmonary Disease. 2018; 15: 118-122.

[2] Van Eeden SF, Sin DD. Oxidative stress in chronic obstructive pulmonary disease: a lung and systemic process. Canadian Respiratory Journal. 2013; 20: 27-29.

[3] Tworek D, Antczak A. Eosinophilic COPD - a distinct phenotype of the disease. Advances in Respiratory Medicine. 2017; 85: 271-276.

[4] Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. European Respiratory Journal. 2014; 44: 1697-1700.

[5] Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? The Lancet Respiratory Medicine. 2017; 5: 747-759.

[6] Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. American Journal of Respiratory and Critical Care Medicine. 2011; 184: 662-671.

[7] Dekkers BGJ, Schaafsma D, Nelemans SA, Zaagsma J, Meurs H. Extracellular matrix proteins differentially regulate airway smooth muscle phenotype and function. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2007; 292: L1405-L1413.

[8] Wang Z, Li R, Zhong R. Extracellular matrix promotes proliferation, migration and adhesion of airway smooth muscle cells in a rat model of chronic obstructive pulmonary disease via upregulation of the PI3K/AKT signaling pathway. Molecular Medicine Reports. 2018; 18: 3143-3152.

[9] Johnson PR, Black JL, Carlin S, Ge Q, Underwood PA. The production of extracellular matrix proteins by human passively sensitized airway smooth-muscle cells in culture: the effect of beclomethasone. American Journal of Respiratory and Critical Care Medicine. 2000; 162: 2145-2151.

[10] White SR, Dorscheid DR, Rabe KF, Wojcik KR, Hamann KJ. Role of very late adhesion integrins in mediating repair of human airway epithelial cell monolayers after mechanical injury. American Journal of Respiratory Cell and Molecular Biology. 1999; 20: 787-796.

[11] Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2010; 298: L715-L731.

[12] Parameswaran K, Willems-Widyastuti A, Alagappan VKT, Radford K, Kranenburg AR, Sharma HS. Role of extracellular matrix and its regulators in human airway smooth muscle biology. Cell Biochemistry and Biophysics. 2006; 44: 139-146.

[13] Johansson O, Erjefält J, Bjermer L, Löfdahl C-G, Westergren-Thorsson G, Hallgren O. Aberrant intracellular expression of laminin α-2 and -5 in bronchiolar epithelium of COPD patients. European Respiratory Journal. 2014; 14: 3955.

[14] Gentry S, Gentry B. Chronic obstructive pulmonary disease: diagnosis and management. American Family Physician. 2017; 95: 433-441.

[15] Pauwels R, Buıst AS, Ma P, Jenkıns C, Hurd S; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. American Journal of Respiratory and Critical Care Medicine. 2001; 46: 798-825.

[16] Kranenburg AR, Willems-Widyastuti A, Mooi WJ, Sterk PJ, Alagappan VKT, de Boer WI, et al. Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. American Journal of Clinical Pathology. 2006; 126: 725-735.

[17] Prabhala P, Wright DB, Robbe P, Bitter C, Pera T, ten Hacken NHT, et al. Laminin α4 contributes to airway remodeling and inflammation in asthma. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2019; 317: L768-L777.

[18] Liesker JJ, Ten Hacken NH, Zeinstra-Smith M, Rutgers SR, Postma DS, Timens W. Reticular basement membrane in asthma and COPD: similar thickness, yet different composition. International Journal of Chronic Obstructive Pulmonary Disease. 2009; 4: 127-135.

[19] Westerhof GA, Korevaar DA, Amelink M, de Nijs SB, de Groot JC, Wang J, et al. Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. European Respiratory Journal. 2015; 46: 688-696.

[20] Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, et al. Blood eosinophil levels as a biomarker in COPD. Respiratory Medicine. 2018; 138: 21-31.

[21] Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2018; 13: 335-349.

[22] Hospers JJ, Schouten JP, Weiss ST, Postma DS, Rijcken B. Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample. Epidemiology. 2000; 11: 261-268.

[23] Nixon J, Newbold P, Mustelin T, Anderson GP, Kolbeck R. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacology & Therapeutics. 2017; 169: 57-77.

[24] George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Therapeutic Advances in Chronic Disease. 2016; 7: 34-51.

[25] Casanova C, Celli BR, de-Torres JP, Martínez-Gonzalez C, Cosio BG, Pinto-Plata V, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. European Respiratory Journal. 2017; 50: 1701162.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time